Comparative Pharmacology
Head-to-head clinical analysis: CYTARABINE versus REDITREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTARABINE versus REDITREX.
CYTARABINE vs REDITREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. It is converted intracellularly to its active triphosphate form, which competes with deoxycytidine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase. It also inhibits DNA repair and RNA synthesis.
REDITREX is a folate analog metabolic inhibitor that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for purine and pyrimidine synthesis. This leads to inhibition of DNA synthesis and cell proliferation.
100-200 mg/m² IV continuous infusion over 24 hours for 7 days (induction) or 1-3 g/m² IV every 12 hours for 3-6 days (high-dose). Intrathecal: 30-100 mg/m² (max 100 mg) once every 2-7 days.
15 mg/m2 intramuscularly or intravenously once weekly; maximum single dose 30 mg.
None Documented
None Documented
Clinical Note
moderateCytarabine + Digoxin
"Cytarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCytarabine + Digitoxin
"Cytarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCytarabine + Deslanoside
"Cytarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCytarabine + Acetyldigitoxin
"Cytarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Initial distribution half-life ~10 min; terminal elimination half-life ~1-3 hours (biphasic); prolongs in renal impairment.
Terminal elimination half-life is 3-10 hours in patients with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Primarily hepatic metabolism (deaminated by cytidine deaminase to inactive uracil arabinoside); renal excretion of unchanged drug accounts for <10% of dose; <1% biliary/fecal.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; minimal biliary/fecal elimination (<10%).
Category C
Category C
Antineoplastic Antimetabolite
Antineoplastic Antimetabolite